Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Preexisting pancreatic acinar cells contribute to acinar cell, but not islet β cell, regeneration
Biva M. Desai, … , Steven D. Leach, Doris A. Stoffers
Biva M. Desai, … , Steven D. Leach, Doris A. Stoffers
Published April 2, 2007
Citation Information: J Clin Invest. 2007;117(4):971-977. https://doi.org/10.1172/JCI29988.
View: Text | PDF
Research Article

Preexisting pancreatic acinar cells contribute to acinar cell, but not islet β cell, regeneration

  • Text
  • PDF
Abstract

It has been suggested that pancreatic acinar cells can serve as progenitors for pancreatic islets, a concept with substantial implications for therapeutic efforts to increase insulin-producing β cell mass in patients with diabetes. We report what we believe to be the first in vivo lineage tracing approach to determine the plasticity potential of pancreatic acinar cells. We developed an acinar cell–specific inducible Cre recombinase transgenic mouse, which, when mated with a reporter strain and pulsed with tamoxifen, resulted in permanent and specific labeling of acinar cells and their progeny. During various time periods of observation and using several models to provoke injury, we failed to observe any chase of the labeled cells into the endocrine compartment, indicating that acinar cells do not normally transdifferentiate into islet β cells in vivo in adult mice. In contrast, we observed a substantial role for replication of preexisting acinar cells in the regeneration of new acinar cells after partial pancreatectomy. These results indicate that mature acinar cells harbor a facultative acinar but not endocrine progenitor capacity.

Authors

Biva M. Desai, Jennifer Oliver-Krasinski, Diva D. De Leon, Cyrus Farzad, Nankang Hong, Steven D. Leach, Doris A. Stoffers

×

Figure 4

Recovery of β cell mass after Ppx and biological efficacy of Ex-4 treatment.

Options: View larger image (or click on image) Download as PowerPoint
Recovery of β cell mass after Ppx and biological efficacy of Ex-4 treatm...
(A) Glucose tolerance tests were performed i.p. 2 weeks after Ppx or sham surgery in mice treated with vehicle or Ex-4 (n = 4–5 per group). Black line denotes sham surgery plus treatment with vehicle, blue dashed line denotes Ppx plus treatment with vehicle, gray line denotes sham surgery plus treatment with Ex-4, and dashed black line denotes Ppx plus treatment with Ex-4. P < 0.05, Ppx plus vehicle versus all other groups; ANOVA. (B) Mass of β cells (in mg) was determined by point counting morphometry 4–5 weeks after surgery. (C) Weight (in g) of the pancreatic remnant at 4–5 weeks after surgery.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts